SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Abiomed Inc. – ‘8-K’ for 8/4/22

On:  Thursday, 8/4/22, at 7:14am ET   ·   For:  8/4/22   ·   Accession #:  950170-22-14469   ·   File #:  1-09585

Previous ‘8-K’:  ‘8-K’ on 6/21/22 for 6/17/22   ·   Next:  ‘8-K’ on 8/12/22 for 8/10/22   ·   Latest:  ‘8-K’ on / for 11/1/22

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/04/22  Abiomed Inc.                      8-K:2,9     8/04/22   11:778K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     61K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    538K 
 6: R1          Document and Entity Information                     HTML     46K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- abmd-20220804_htm                   XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- abmd-20220804_lab                     XML     53K 
 5: EX-101.PRE  XBRL Presentations -- abmd-20220804_pre              XML     33K 
 3: EX-101.SCH  XBRL Schema -- abmd-20220804                         XSD     11K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    18K 
11: ZIP         XBRL Zipped Folder -- 0000950170-22-014469-xbrl      Zip     42K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C:  C: 
  8-K  
 i false i 000081509400008150942022-08-042022-08-04

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i August 4, 2022

 

img17695935_0.jpg 

 i ABIOMED, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 i Delaware

 i 001-09585

 i 04-2743260

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 i 22 Cherry Hill Drive
 i Danvers,  i Massachusetts  i 01923

(Address of Principal Executive Offices, including Zip Code)

( i 978)  i 646-1400

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol

Name of each exchange on which registered

 i Common Stock, $0.01 par value

 i ABMD

 i The NASDAQ Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

 i 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 i 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 


 

Item 2.02 Results of Operations and Financial Condition.

 

On August 4, 2022, ABIOMED, Inc. (the “Company,” “we” or “us”) issued a press release reporting our financial results for our first quarter ended June 30, 2022. A copy of the press release is set forth as Exhibit 99.1 and is incorporated herein by reference. The information contained in this report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

 

Caution Concerning Forward-Looking Statements

 

This Form 8-K contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such statements include, but are not limited to, those regarding our financial performance and the impact of the COVID-19 pandemic on our operations and financial results and are subject to, among other risks, the COVID-19 pandemic and any related policies and actions by governments or other third parties. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

 

Description

99.1

 

Press release dated August 4, 2022

 

 

 

104

 

Cover Page Interactive Data File (embedded with the Inline XBRL document)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

ABIOMED, Inc.

 

 

 

 

 

 

 

 

By:

/s/ Todd A. Trapp

 

 

 

 

 

Todd A. Trapp

Executive Vice President and Chief Financial Officer

(Authorized Signatory)

Date: August 4, 2022

 

 

 

 

 

 

 



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:8/4/22None on these Dates
6/30/22
 List all Filings 
Top
Filing Submission 0000950170-22-014469   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2022 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Dec. 2, 5:59:07.1pm ET